Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Common Equity (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Common Equity data on record, last reported at $10.4 million in Q3 2025.

  • For Q3 2025, Common Equity rose 108.04% year-over-year to $10.4 million; the TTM value through Sep 2025 reached $10.4 million, up 108.04%, while the annual FY2024 figure was $3.9 million, 375.11% up from the prior year.
  • Common Equity reached $10.4 million in Q3 2025 per COEP's latest filing, up from $7.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $10.4 million in Q3 2025 and bottomed at -$9.7 million in Q2 2021.
  • Average Common Equity over 5 years is $1.7 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 234.76% in 2024, then soared 2383.47% in 2025.
  • A 5-year view of Common Equity shows it stood at $2.4 million in 2021, then skyrocketed by 89.45% to $4.5 million in 2022, then tumbled by 81.72% to $813964.0 in 2023, then soared by 375.11% to $3.9 million in 2024, then soared by 168.04% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $10.4 million in Q3 2025, $7.1 million in Q2 2025, and $7.5 million in Q1 2025.